Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2024 am IST			5-day change	1st Jan Change
17.88 ^USD	+4.56%		-0.72%	+63.44%

10/05	Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	MT
09/05	Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Edgewise Therapeutics Announces Board Appointments

September 17, 2019 at 06:30 pm IST

Edgewise Therapeutics announced that Joining the Board of Directors will be Kenneth Harrison, Ph.D., Principal at Novo Ventures and Jonathan Root, M.D., General Partner at USVP; Robert Jackson, M.D., Partner and CSO at Deerfield will join as a Board Observer.

Latest news about Edgewise Therapeutics, Inc.

Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating	10/05	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors	07/05	CI
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial	06/05	MT
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy	06/05	CI
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	23/04	MT
RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk	22/04	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	16/04	MT
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	16/04	MT
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	16/04	CI
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28/03	CI
Piper Sandler Starts Edgewise Therapeutics With Overweight Rating, $48 Price Target	07/03	MT
Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating	23/02	MT
Edgewise Therapeutics Full Year 2023 Net Loss Widens	22/02	MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation	14/02	MT
Edgewise Shares Rise Premarket on FDA Fast-Track Designation	13/02	DJ
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	13/02	CI
Edgewise Therapeutics Insider Sold Shares Worth $596,805, According to a Recent SEC Filing	10/02	MT
Edgewise Therapeutics Insider Sold Shares Worth $1,419,759, According to a Recent SEC Filing	26/01	MT
Edgewise Therapeutics Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing	26/01	MT
Top Midday Gainers	19/01	MT
Edgewise Therapeutics Surging After Pricing $240 Million Stock Sale Above Last Close	19/01	MT
Edgewise Therapeutics Insider Sold Shares Worth $1,610,097, According to a Recent SEC Filing	29/12	MT

Chart Edgewise Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.88 USD

Average target price

32.5 USD

Spread / Average Target

+81.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EDGEWISE THERAPEUTICS, INC.	+63.44%	167Cr
MODERNA, INC.	+48.54%	5.66TCr
LONZA GROUP AG	+37.15%	3.93TCr
IQVIA HOLDINGS INC.	-6.02%	3.96TCr
CELLTRION, INC.	-6.90%	2.83TCr
ICON PUBLIC LIMITED COMPANY	+12.97%	2.64TCr
ALNYLAM PHARMACEUTICALS, INC.	-16.91%	2.01TCr
MEDPACE HOLDINGS, INC.	+31.71%	1.25TCr
UNITED THERAPEUTICS CORPORATION	+28.18%	1.25TCr
BIO-TECHNE CORPORATION	+0.38%	1.22TCr

Other Biotechnology & Medical Research